Exhibit 17.2
Response letter of Joseph Klein III, dated March 31, 2010
| | |
| March 31, 2010 | | |
| |
The Board of Directors c/o G. Eric Davis, Senior Vice President and General Counsel | | |
| BioMarin Pharmaceutical Inc. | | |
| 105 Digital Drive | | |
| Novato, California 94949 | | VIA EMAIL AND FEDEX |
RE: CURRENT REPORT ON FORM 8-K OF BIOMARIN PHARMACEUTICAL, INC., FILED ON MARCH 24, 2010 (THE “MARCH 24, 2010 8-K”)
Ladies and Gentlemen:
I am providing this letter to BioMarin Pharmaceutical Inc. (“BioMarin” or the“Company”) as permitted by Section 5.02(a)(3)(ii) of Form 8-K. I have carefully read the March 24, 2010 8-K. I continue to stand by both the spirit and content of my letter of resignation dated March 19, 2010 (the “Resignation Letter”) to the Board of Directors of BioMarin. I find it unfortunate that BioMarin chose to characterize my disagreements in the manner that it did. I thought that my letter was clear, concise and presented the facts in a balanced manner. I would have hoped that BioMarin would have done the same.
While I am no longer director or BioMarin and not certain what has transpired since my resignation, based on the facts that I was presented with, I did not agree with the manner in which the Company chose to conduct the internal investigation referenced under the heading, “Disagreement Regarding How to Conduct an Ongoing Investigation Regarding a Serious Matter”. I believe that a difference process should have been followed.
I do not believe it is productive or in the best interests of shareholders and employees to continue a dialogue on these issues at this point in time.
BioMarin’s people are talented, very hardworking, and have brought three important biopharmaceutical products to patients with unmet needs. I wish these people well, and suggest that we all move ahead in the best interest of patients, shareholders, and these talented employees.
|
| Very truly yours, |
|
/s/ Joseph Klein III |
| Joseph Klein, III |
